Early tumor volume change as a novel CT RECIST indicator for predicting pathological response and prognosis in NSCLC patients undergoing immunotherapy
Fan Xu(ShanghaiTech University), Yuanyong Wang(Weifang Medical University), Xinying Xue(Capital Medical University), Mei Xie(Chinese PLA General Hospital), Jiannan Yao(Beijing Chaoyang Emergency Medical Center), Xidong Ma(Beijing Shijitan Hospital), Xinyu Bao(Capital Medical University), Chongchong Wu(Weifang Medical University), Xin Zhang(Qilu Hospital of Shandong University), Jie Gao(Chinese PLA General Hospital), Yang Yang(Chengdu University of Traditional Chinese Medicine), Yuyao Zhang(Massachusetts General Hospital), Jie Zheng(Chinese Academy of Sciences), Yimiao Feng(ShanghaiTech University), Jie Yao(Tang Du Hospital), Jialin Song(Qingdao University), Tianjiao Jiang(Chinese PLA General Hospital), Xuming He(University of Toronto), Zhiqiang Xue(Weifang Medical University)
Cited by 0
Related Papers
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
|Cell|2024|272
MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating <i>SOCS1</i>, <i>SOCS6</i>, and <i>PTEN</i>
|Oncotarget|2016|182
circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637
|EBioMedicine|2019|127
Plasmid-mediated quinolone resistance – current knowledge and future perspectives
|Journal of International Medical Research|2013|70
An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction
|Science Advances|2023|65